R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study
NCT04842487
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
80
Enrollment
OTHER
Sponsor class
Conditions
DLBCL
Interventions
DRUG:
R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide，hydroxyldaunorubicin，Vincristine，Prednisone）)
Sponsor
Sun Yat-sen University